Specialized Research Niche Redoxis operates as a boutique CRO focused on inflammation and autoimmune conditions, making it an ideal partner for biotech and pharma clients seeking specialized preclinical efficacy and mechanism of action studies in these therapeutic areas.

Recent Grant Funding The company secured an €0.8 million grant from EUREKA Eurostars, indicating strong support and interest in its innovative projects, which could lead to new research collaborations and funding opportunities for clients involved in similar early-stage R&D.

Innovative Screening Platform Redoxis is developing a cutting-edge Alphavirus-based screening platform, AlphaSelect, opening avenues for partners interested in antiviral research, neurodegenerative disease modeling, and novel therapeutic target validation.

Growing Tech Capabilities The company's capability to perform comprehensive in vivo, ex vivo, and in vitro assays combined with immunology and cell-based studies demonstrates a broad service portfolio, suitable for clients needing integrated preclinical testing and sophisticated immune profiling.

Market Positioning With a small but focused team and specialization in immunology-driven research, Redoxis is well-positioned to serve emerging biotech startups and pharmaceutical companies seeking expert preclinical testing services within inflammation and autoimmune research domains.